At the time of writing, Harmony Biosciences Holdings Inc [HRMY] stock is trading at $36.45, up 7.65%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The HRMY shares have gain 4.80% over the last week, with a monthly amount glided 11.43%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Harmony Biosciences Holdings Inc [NASDAQ: HRMY] stock has seen the most recent analyst activity on December 17, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $75. On September 10, 2024, UBS initiated with a Buy rating and assigned a price target of $56 on the stock. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $48 on June 21, 2024. BofA Securities downgraded its rating to a Underperform but $30 remained the price target by the analyst firm on January 02, 2024. Goldman downgraded its rating to Sell for this stock on September 25, 2023, and downed its price target to $31. In a note dated September 07, 2023, Berenberg initiated an Buy rating and provided a target price of $59 on this stock.
For the past year, the stock price of Harmony Biosciences Holdings Inc fluctuated between $28.14 and $41.61. Currently, Wall Street analysts expect the stock to reach $45.33 within the next 12 months. Harmony Biosciences Holdings Inc [NASDAQ: HRMY] shares were valued at $36.45 at the most recent close of the market. An investor can expect a potential return of 24.36% based on the average HRMY price forecast.
Analyzing the HRMY fundamentals
According to Harmony Biosciences Holdings Inc [NASDAQ:HRMY], the company’s sales were 681.88M for trailing twelve months, which represents an 16.08% jump. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at 0.26%, Pretax Profit Margin comes in at 0.26%, and Net Profit Margin reading is 0.18%. To continue investigating profitability, this company’s Return on Assets is posted at 0.13, Equity is 0.23 and Total Capital is 0.23. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.31.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 35.02 points at the first support level, and at 33.58 for the second support level. However, for the 1st resistance point, the stock is sitting at 37.52, and for the 2nd resistance point, it is at 38.59.
Ratios To Look Out For
It is important to note that Harmony Biosciences Holdings Inc [NASDAQ:HRMY] has a current ratio of 3.24. As well, the Quick Ratio is 3.20, while the Cash Ratio is 2.4. Considering the valuation of this stock, the price to sales ratio is 3.05, the price to book ratio is 3.48 and price to earnings (TTM) ratio is 17.26.
Transactions by insiders
Recent insider trading involved JEFFREY G DIERKS, Officer, that happened on Jan 13 ’25 when 47162.0 shares were purchased. 10% Owner, Valor IV Pharma Holdings, LLC completed a deal on Nov 01 ’24 to sell 4.0 million shares. Meanwhile, 10% Owner Valor IV Pharma Holdings, LLC sold 0.6 million shares on Nov 05 ’24.
